We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

176 hedge funds and large institutions have $2.76B invested in Clovis Oncology, Inc. in 2015 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 16

18% more funds holding in top 10

Funds holding in top 10: 1113 (+2)

16% more funds holding

Funds holding: 152176 (+24)

15% more capital invested

Capital invested by funds: $2.41B → $2.76B (+$354M)

5% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 55

6% less call options, than puts

Call options by funds: $42.9M | Put options by funds: $45.9M

Holders
176
Holders Change
+24
Holders Change %
+15.79%
% of All Funds
4.74%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.35%
New
40
Increased
58
Reduced
55
Closed
16
Calls
$42.9M
Puts
$45.9M
Net Calls
-$2.92M
Net Calls Change
+$24.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$318M -$45.3M -529,250 -13%
PHS
2
PFM Health Sciences
California
$238M +$38.3M +446,905 +20%
PAI
3
Palo Alto Investors
California
$211M +$23.9M +279,260 +13%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$196M -$4.27M -49,845 -2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$158M +$13M +151,772 +9%
O
6
OppenheimerFunds
New York
$133M +$1.72M +20,140 +1%
NMC
7
NEA Management Company
Maryland
$100M -$97.6M -1,139,891 -50%
BFA
8
BlackRock Fund Advisors
California
$91.3M -$2.32M -27,131 -3%
O
9
OrbiMed
New York
$88.3M +$411K +4,800 +0.5%
CPCM
10
Clifton Park Capital Management
Delaware
$72.7M
Lord, Abbett & Co
11
Lord, Abbett & Co
New Jersey
$71.5M +$20.8M +243,048 +43%
RG
12
Redmile Group
California
$66.7M -$12.1M -141,400 -16%
VAM
13
Visium Asset Management
New York
$66M +$8.03M +93,831 +14%
State Street
14
State Street
Massachusetts
$62M +$2.31M +26,957 +4%
BIT
15
BlackRock Institutional Trust
California
$60.7M -$2.47M -28,821 -4%
BB
16
BB Biotech
Switzerland
$54.3M
TCM
17
TimesSquare Capital Management
New York
$43.1M -$543K -6,345 -1%
Citadel Advisors
18
Citadel Advisors
Florida
$42.4M +$25.6M +298,864 +163%
VVM
19
Versant Venture Management
California
$35.8M -$34.9M -407,417 -50%
JHIU
20
Janus Henderson Investors US
Colorado
$29.1M +$229K +2,676 +0.8%
Morgan Stanley
21
Morgan Stanley
New York
$27.6M -$676K -7,899 -2%
CCM
22
Consonance Capital Management
New York
$26.6M +$25.9M +303,131 New
Northern Trust
23
Northern Trust
Illinois
$25.3M -$447K -5,225 -2%
PC
24
PointState Capital
New York
$22.4M +$4.71M +55,000 +28%
BA
25
BlackRock Advisors
Delaware
$22.3M +$2.27M +26,491 +12%

CLVS Hedge Fund Activity: Q2 2015 in Review

176 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2015, worth a combined $2.76B — up 15% from $2.41B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new CLVS positions and 16 closed out — a net gain of 24 holders — while 58 added to existing stakes and 55 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $38.3M. The largest seller was NEA Management Company, cutting an estimated $97.6M.

  • 176 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2015, up from 152 in Q1 2015.
  • Funds reported $2.76B of Clovis Oncology, Inc. stock for Q2 2015, up 15% quarter-over-quarter.
  • 40 funds opened new Clovis Oncology, Inc. positions in Q2 2015 and 16 closed out, a net change of +24 holders.
  • The largest Clovis Oncology, Inc. buyer in Q2 2015 was PFM Health Sciences, an estimated $38.3M added.
  • The largest Clovis Oncology, Inc. seller in Q2 2015 was NEA Management Company, an estimated $97.6M sold.

Based on aggregated 13F filings for Q2 2015.